CommercialPrior AuthLow impact
Pharmacy coverage changes
Harvard Pilgrim Health Care·Dermatology·Pharmacy
Effective date
Feb 1, 2026
We identified it
Jun 20, 2026
Summary
Point32Health (Harvard Pilgrim Commercial, Tufts Health Plan Commercial, Tufts Health Direct) is updating prior authorization requirements for Vtama, a dermatological immunomodulator. The changes include updated prerequisite trials and removal of reauthorization criteria, effective February 1, 2026.
Action Required
Before February 1, 2026: Billing team should review updated Dermatological Immunomodulators PMNG guidelines on Point32Health provider website for Vtama prescriptions. Update prior authorization workflows to reflect new prerequisite trial requirements and note that reauthorization is no longer required for existing patients.